Responsibility Statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements of the Merck Group give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group for the remaining months of the financial year.

Darmstadt, November 14, 2012



Karl-Ludwig Kley



Kai Beckmann

Stefan Oschmann

Bernd Reckmann



Matthias Zachert

Interim Consolidated Financial Statements as of September 30, 2012

Consolidated Income Statement

€ million	Q3 2012	Q3 2011*	Jan.–Sept. 2012	Jan.–Sept. 2011*
Sales	**2,721.7**	**2,434.3**	**8,028.7**	**7,381.4**
Royalty, license and commission income	119.4	97.3	309.4	269.3
Total revenues	**2,841.0**	**2,531.6**	**8,338.1**	**7,650.7**
Cost of sales	–787.6	–679.1	–2,344.1	–2,077.9
Gross profit	**2,053.4**	**1,852.5**	**5,994.0**	**5,572.8**
Marketing and selling expenses	–598.0	–584.6	–1,801.8	–1,778.5
Royalty, license and commission expenses	–161.6	–133.9	–433.4	–363.7
Administration expenses	–141.6	–132.6	–420.6	–397.1
Other operating expenses and income	–245.1	–86.3	–878.4	–301.5
Research and development	–370.8	–370.2	–1,156.5	–1,117.3
Amortization of intangible assets	–218.2	–212.9	–651.8	–780.1
Investment result	–	–0.1	0.5	1.9
Operating result (EBIT)	**318.1**	**331.8**	**651.9**	**836.4**
Financial result	–58.2	–72.4	–193.9	–219.0
Profit before income tax	**260.0**	**259.4**	**458.0**	**617.5**
Income tax	–71.3	–32.3	–154.7	–135.6
Profit after tax	**188.7**	**227.2**	**303.3**	**481.9**
of which attributable to Merck KGaA shareholders (net income)	185.5	223.9	294.9	473.6
of which non-controlling interest	3.2	3.3	8.3	8.2
Earnings per share (in €)				
basic	0.85	1.03	1.36	2.18
diluted	0.85	1.03	1.36	2.18

*Previous year's figures have been adjusted, see explanations on page 27.

Consolidated Statement of Comprehensive Income

€ million	Q3 2012	Q3 2011*	Jan.–Sept. 2012	Jan.–Sept. 2011*
Profit after tax	**188.7**	**227.2**	**303.3**	**481.9**
Available-for-sale financial assets				
Fair value adjustments	1.1	–3.2	1.2	26.1
Reclassification to income statement	–	0.2	–	–27.0
Deferred taxes	–	0.8	–	1.4
Changes recognized in equity	**1.1**	**–2.2**	**1.2**	**0.5**
Derivative financial instruments				
Fair value adjustments	7.9	–45.8	–43.1	–32.6
Reclassification to income statement	10.7	–3.2	65.0	–6.8
Deferred taxes	–3.0	7.8	–1.8	7.6
Changes recognized in equity	**15.6**	**–41.2**	**20.2**	**–31.8**
Remeasurement of the net defined benefit liability				
Changes in remeasurement	–97.1	–2.0	–106.9	–
Deferred taxes	16.6	0.8	14.7	0.9
Changes recognized in equity	**–80.5**	**–1.2**	**–92.2**	**0.9**
Exchange differences on translating foreign operations				
Changes taken directly to equity	–8.6	–32.7	33.4	–75.1
Reclassification to income statement	–	–	–	3.5
Changes recognized in equity	**–8.6**	**–32.7**	**33.4**	**–71.6**
Gains/losses recognized immediately in equity	**–72.4**	**–77.3**	**–37.4**	**–102.0**
Comprehensive income	**116.4**	**149.9**	**265.9**	**379.9**
of which attributable to Merck KGaA shareholders	112.5	146.2	258.0	374.4
of which attributable to non-controlling interest	3.9	3.7	7.9	5.5

*Previous year's figures have been adjusted, see explanations on page 27.

Consolidated Balance Sheet

€ million	Sept. 30, 2012	Dec. 31, 2011*
Current assets		
Cash and cash equivalents	1,484.7	937.8
Marketable securities and financial assets	1,443.3	1,117.1
Trade accounts receivable	2,206.7	2,328.3
Inventories	1,609.6	1,691.1
Other current assets	275.1	252.0
Income tax receivables	118.4	72.7
	7,137.7	**6,399.0**
Non-current assets		
Intangible assets	11,178.5	11,764.3
Property, plant and equipment	2,950.8	3,113.4
Non-current financial assets	102.1	60.3
Other non-current assets	57.4	54.9
Deferred tax assets	846.5	730.0
	15,135.3	**15,722.9**
Total assets	**22,273.1**	**22,121.9**
Current liabilities		
Current financial liabilities	1,674.0	1,394.4
Trade accounts payable	1,297.9	1,100.8
Other current liabilities	918.4	1,102.1
Income tax liabilities	429.4	399.4
Current provisions	678.0	365.5
	4,997.8	**4,362.2**
Non-current liabilities		
Non-current financial liabilities	3,380.9	4,144.9
Other non-current liabilities	21.8	43.6
Non-current provisions	820.1	617.0
Provisions for pensions and other post-employment benefits	1,280.4	1,140.3
Deferred tax liabilities	1,206.0	1,319.6
	6,709.2	**7,265.4**
Net equity		
Equity capital	565.2	565.2
Reserves	8,683.2	8,672.6
Gains/losses recognized immediately in equity	1,265.3	1,210.2
Equity attributable to Merck KGaA shareholders	**10,513.7**	**10,448.0**
Non-controlling interest	52.5	46.3
	10,566.1	**10,494.3**
Total liabilities and stockholders' equity	**22,273.1**	**22,121.9**

*Previous year's figures have been adjusted, see explanations on page 27.

Consolidated Cash Flow Statement

€ million	Jan.–Sept. 2012	Jan.–Sept. 2011*
Profit after tax	**303.3**	**481.9**
Depreciation/amortization/impairment losses/write-ups	1,037.4	1,253.5
Changes in inventories	93.4	–87.5
Changes in trade accounts receivable	139.3	–74.7
Changes in trade accounts payable	192.1	–74.3
Changes in provisions	550.9	22.7
Changes in other assets and liabilities	–216.8	–121.7
Neutralization of gain/loss on disposals of assets	–32.0	–205.7
Other non-cash income and expenses	6.1	22.6
Net cash flows from operating activities	**2,073.9**	**1,216.7**
Purchase of intangible assets	–88.0	–35.8
Purchase of property, plant and equipment	–181.1	–246.0
Acquisitions	–4.1	–84.3
Investments in financial assets	–14.6	–6.5
Disposal of non-current assets	63.6	557.3
Purchase/sale of marketable securities	10.5	–21.3
Changes in other financial assets	–370.8	–912.0
Net cash flows from investing activities	**–584.4**	**–748.6**
Dividend payments	–102.2	–84.5
Profit transfers to E. Merck KG and changes in reserves	–92.1	–233.0
Changes in liabilities to E. Merck KG	–143.2	81.5
Repayment of bonds	–500.0	–
Changes in current and non-current financial liabilities	–106.2	–37.6
Net cash flows from financing activities	**–943.7**	**–273.6**
Changes in cash and cash equivalents	**545.7**	**194.5**
Changes in cash and cash equivalents due to currency translation	1.3	–2.2
Cash and cash equivalents as of January 1 (Group balance sheet)	937.8	943.7
Plus cash and cash equivalents previously in assets held for sale	–	1.2
Cash and cash equivalents as of September 30	**1,484.7**	**1,137.2**

*Previous year's figures have been adjusted, see explanations on page 27.

Consolidated Statement of Changes in Net Equity

	Equity capital		Reserves			Gains/losses recognized immediately in equity					
€ million	General partner's equity Merck KGaA	Sub-scribed capital Merck KGaA	Capital reserves (share premium) Merck KGaA	Retained earn-ings/Net retained profit	Remea-surement defined benefit liability	Available-for-sale financial assets	Derivative financial instru-ments	Currency translation difference	Equity attributable to Merck KGaA share-holders	Non-con-trolling interest	Equity
Balance as of January 1, 2011	**397.2**	**168.0**	**3,813.7**	**5,040.9**	**–370.4**	**–3.1**	**–61.1**	**1,344.6**	**10,329.8**	**42.0**	**10,371.8**
Adjustment IAS 19	–	–	–	–0.6	5.4	–	–	–	4.8	–	4.8
Balance as of January 1, 2011 adjusted	**397.2**	**168.0**	**3,813.7**	**5,040.3**	**–365.0**	**–3.1**	**–61.1**	**1,344.6**	**10,334.6**	**42.0**	**10,376.6**
Profit after tax*	–	–	–	473.6	–	–	–	–	473.6	8.2	481.9
Gains/losses recognized immediately in equity*	–	–	–	–	0.9	0.5	–31.8	–68.9	–99.3	–2.7	–102.0
Comprehensive income*	**–**	**–**	**–**	**473.6**	**0.9**	**0.5**	**–31.8**	**–68.9**	**374.4**	**5.5**	**379.9**
Dividend payments	–	–	–	–80.8	–	–	–	–	–80.8	–3.8	–84.6
Profit transfers to/from E. Merck KG including transfers to reserves	–	–	–	–233.0	–	–	–	–	–233.0	–	–233.0
Changes in scope of consolidation/Other	–	–	–	–1.8	–	–	–	–	–1.8	1.4	–0.4
Balance as of September 30, 2011*	**397.2**	**168.0**	**3,813.7**	**5,198.3**	**–364.1**	**–2.6**	**–92.9**	**1,275.7**	**10,393.3**	**45.1**	**10,438.4**
Balance as of January 1, 2012	**397.2**	**168.0**	**3,813.7**	**5,248.7**	**–390.7**	**0.8**	**–94.6**	**1,304.0**	**10,447.1**	**46.3**	**10,493.4**
Adjustment IAS 19	–	–	–	–11.6	12.5	–	–	–	0.9	–	0.9
Balance as of January 1, 2012 adjusted	**397.2**	**168.0**	**3,813.7**	**5,237.1**	**–378.2**	**0.8**	**–94.6**	**1,304.0**	**10,448.0**	**46.3**	**10,494.3**
Profit after tax	–	–	–	294.9	–	–	–	–	294.9	8.3	303.3
Gains/losses recognized immediately in equity	–	–	–	–	–92.1	1.2	20.2	33.7	–37.0	–0.4	–37.4
Comprehensive income	**–**	**–**	**–**	**294.9**	**–92.1**	**1.2**	**20.2**	**33.7**	**258.0**	**7.9**	**265.9**
Dividend payments	–	–	–	–96.9	–	–	–	–	–96.9	–5.3	–102.2
Profit transfers to/from E. Merck KG including transfers to reserves	–	–	–	–92.1	–	–	–	–	–92.1	–	–92.1
Changes in scope of consolidation/Other	–	–	–	–3.3	–	–	–	–	–3.3	3.6	0.2
Balance as of September 30, 2012	**397.2**	**168.0**	**3,813.7**	**5,339.7**	**–470.3**	**2.0**	**–74.4**	**1,337.7**	**10,513.7**	**52.5**	**10,566.1**

*Previous year's figures have been adjusted, see explanations on page 27.